05 Jan 2021
Imperial peanut allergy biomarker study underway
Allergy Therapeutics has initiated an ex vivo biomarker study with Imperial College London for its novel VLP-based peanut allergy vaccine candidate. The information generated from this study will be used to support clinical development of the peanut vaccine programme and will establish the starting dose of the first-in-human Phase I study. The IND application will be filed with the FDA in 2021, with the Phase I trial also planned to start this year.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Imperial peanut allergy biomarker study underway
Allergy Therapeutics plc (AGY:LON) | 2.8 0 0.0% | Mkt Cap: 135.8m
- Published:
05 Jan 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Allergy Therapeutics has initiated an ex vivo biomarker study with Imperial College London for its novel VLP-based peanut allergy vaccine candidate. The information generated from this study will be used to support clinical development of the peanut vaccine programme and will establish the starting dose of the first-in-human Phase I study. The IND application will be filed with the FDA in 2021, with the Phase I trial also planned to start this year.